NEW YORK ( TheStreet) -- Shares of Seattle Genetics (Nasdaq: SGEN) were gapping down Friday morning with an open price 13.9% lower than Thursday's closing price. The stock closed at $21.96 Thursday and opened today's trading at $18.90. The average volume for Seattle has been 2.4 million shares per day over the past 30 days. Seattle has a market cap of $2.5 billion and is part of the health care sector and drugs industry. Shares are up 49% year to date as of the close of trading on Thursday. Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. TheStreet Ratings rates Seattle as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. You can view the full Seattle Ratings Report. Get more investment ideas from our investment research center. Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.